Skip to main content

Table 1 Results of immunohistochemistry

From: High survivin expression as a risk factor in patients with anal carcinoma treated with concurrent chemoradiotherapy

 

Patients

 

n (%)

Percentage of immunopositive cells:

 

0–25%

1 (2)

26–50%

6 (10)

51–75%

10 (16)

76–100%

45 (72)

Staining intensity:

 

1+

6 (10)

2+

30 (48)

3+

26 (42)

Individual labeling score:

 

1–3

6 (10)

4–8

30 (48)

9–12

26 (42)

Dichotomized labeling score:

≤ 8

36 (58)

>8

26 (42)